WO2004016248A8 - Forme galenique pour la delivrance colique de principes actifs - Google Patents
Forme galenique pour la delivrance colique de principes actifsInfo
- Publication number
- WO2004016248A8 WO2004016248A8 PCT/FR2003/002474 FR0302474W WO2004016248A8 WO 2004016248 A8 WO2004016248 A8 WO 2004016248A8 FR 0302474 W FR0302474 W FR 0302474W WO 2004016248 A8 WO2004016248 A8 WO 2004016248A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- targeted delivery
- active principles
- colon targeted
- galenic formulation
- colon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03758212T ATE432066T1 (de) | 2002-08-09 | 2003-08-06 | Arzneimittel für die dickdarmverabreichung von wirkstoffen |
BR0313469-5A BR0313469A (pt) | 2002-08-09 | 2003-08-06 | Forma galêmica para a liberação cólica de princìpios ativos |
JP2004528586A JP2006500359A (ja) | 2002-08-09 | 2003-08-06 | 有効成分の結腸標的指向送達用ガレヌス製剤形態 |
EP03758212A EP1526841B1 (fr) | 2002-08-09 | 2003-08-06 | Forme galenique pour la delivrance colique de principes actifs |
CA002495291A CA2495291A1 (fr) | 2002-08-09 | 2003-08-06 | Forme galenique pour la delivrance colique de principes actifs |
US10/524,318 US7485294B2 (en) | 2002-08-09 | 2003-08-06 | Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof |
MXPA05001607A MXPA05001607A (es) | 2002-08-09 | 2003-08-06 | Forma galenica para suministro de ingredientes activos dirigido al colon. |
AU2003274229A AU2003274229B2 (en) | 2002-08-09 | 2003-08-06 | Galenic formulation for colon targeted delivery of active ingredients |
DE60327772T DE60327772D1 (de) | 2002-08-09 | 2003-08-06 | Arzneimittel für die dickdarmverabreichung von wirkstoffen |
CN038213656A CN1681480B (zh) | 2002-08-09 | 2003-08-06 | 用于活性成分结肠靶向释放的盖仑制剂 |
US12/345,647 US7833765B2 (en) | 2002-08-09 | 2008-12-29 | Galenic formulation for colon-targeted delivery of active ingredients |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/10151 | 2002-08-09 | ||
FR0210151A FR2843301B1 (fr) | 2002-08-09 | 2002-08-09 | Forme galenique pour la delivrance colique de principes actifs |
FR0213514A FR2843302B1 (fr) | 2002-08-09 | 2002-10-29 | Forme galenique pour la delivrance colique de principes actifs |
FR02/13514 | 2002-10-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/524,318 A-371-Of-International US7485294B2 (en) | 2002-08-09 | 2003-08-06 | Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereof |
US12/345,647 Continuation US7833765B2 (en) | 2002-08-09 | 2008-12-29 | Galenic formulation for colon-targeted delivery of active ingredients |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004016248A2 WO2004016248A2 (fr) | 2004-02-26 |
WO2004016248A3 WO2004016248A3 (fr) | 2004-04-08 |
WO2004016248A8 true WO2004016248A8 (fr) | 2004-05-21 |
Family
ID=30772009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/002474 WO2004016248A2 (fr) | 2002-08-09 | 2003-08-06 | Forme galenique pour la delivrance colique de principes actifs |
Country Status (14)
Country | Link |
---|---|
US (2) | US7485294B2 (fr) |
EP (2) | EP1992336A3 (fr) |
JP (1) | JP2006500359A (fr) |
KR (1) | KR101080577B1 (fr) |
CN (1) | CN1681480B (fr) |
AT (1) | ATE432066T1 (fr) |
AU (1) | AU2003274229B2 (fr) |
BR (1) | BR0313469A (fr) |
CA (1) | CA2495291A1 (fr) |
DE (1) | DE60327772D1 (fr) |
ES (1) | ES2327630T3 (fr) |
FR (1) | FR2843302B1 (fr) |
MX (1) | MXPA05001607A (fr) |
WO (1) | WO2004016248A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4694145B2 (ja) * | 2004-05-17 | 2011-06-08 | 株式会社 メドレックス | 経口腸溶性製剤 |
JP2008529996A (ja) * | 2005-02-09 | 2008-08-07 | ダ・ボルテラ | 活性因子の大腸送達 |
WO2006122835A1 (fr) * | 2005-05-18 | 2006-11-23 | Da Volterra | Administration colonique d'adsorbants |
JP4962888B2 (ja) * | 2005-06-03 | 2012-06-27 | 株式会社 メドレックス | 経口腸溶性医薬組成物 |
US8048413B2 (en) * | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
US8273376B2 (en) | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
US20080124279A1 (en) * | 2006-11-17 | 2008-05-29 | Antoine Andremont | Colonic delivery using Zn/pectin beads with a Eudragit coating |
FI119678B (fi) * | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
GB0714226D0 (en) * | 2007-07-20 | 2007-08-29 | Therapeutics Ltd E | anti-bacterial combination therapy |
US20100239682A1 (en) * | 2007-09-17 | 2010-09-23 | Antoine Andremont | Colonic delivery of antimicrobial agents |
GB0719771D0 (en) * | 2007-10-10 | 2007-11-21 | Therapeutics Ltd E | Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma |
GB0813211D0 (en) | 2008-07-18 | 2008-08-27 | E Therapeutics Plc | Antibacterial combination therapy for the treatment of gram positive bacterial infections |
FR2950252B1 (fr) * | 2009-09-23 | 2012-01-20 | Centre Nat Rech Scient | Forme galenique capable d'adsorber de maniere specifique les molecules indesirables |
EP2538930B1 (fr) | 2010-02-23 | 2016-06-15 | Da Volterra | Formulation pour l'administration orale d'adsorbants dans l'intestin |
FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
AU2015247382B2 (en) | 2014-04-17 | 2020-04-23 | Theriva Biologics, Inc. | Beta-lactamases with improved properties for therapy |
WO2016033327A1 (fr) | 2014-08-28 | 2016-03-03 | Synthetic Biologics, Inc. | Production de bêta-lactamase à partir d'e-coli |
EP3204495B1 (fr) | 2014-10-08 | 2020-04-22 | Synthetic Biologics, Inc. | Formulations de bêta-lactamase et utilisations de celles-ci |
FR3027307B1 (fr) | 2014-10-16 | 2016-11-04 | Azurrx Sas | Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant |
EP3236993B1 (fr) | 2014-12-23 | 2023-09-13 | Theriva Biologics, Inc. | Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux |
JP6810697B2 (ja) | 2015-02-23 | 2021-01-13 | シンセティック・バイオロジクス・インコーポレイテッド | 腸内マイクロバイオームの保護のために抗生物質と共に使用するカルバペネマーゼ |
EP3265119B1 (fr) | 2015-03-06 | 2023-10-11 | Theriva Biologics, Inc. | Dosage de beta-lactamase sûr et efficace pour la protection du microbiome |
US10182993B2 (en) | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
US10988749B2 (en) | 2016-02-23 | 2021-04-27 | Da Volterra | Beta-lactamase variants |
EP3420078B1 (fr) | 2016-02-23 | 2022-05-25 | Da Volterra | Variants de beta-lactamase |
BR112020000196A2 (pt) | 2017-07-07 | 2020-07-07 | Epicentrx, Inc. | composições para administração parenteral de agentes terapêuticos |
BR112020007974A2 (pt) | 2017-10-25 | 2020-10-27 | Da Volterra | variantes de beta- lactamase |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959457A (en) * | 1970-06-05 | 1976-05-25 | Temple University | Microparticulate material and method of making such material |
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
SE459005B (sv) * | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
FR2608456B1 (fr) * | 1986-12-18 | 1993-06-18 | Mero Rousselot Satia | Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention |
FR2613624B1 (fr) * | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
US4963368A (en) * | 1988-04-18 | 1990-10-16 | Nabisco Brands, Inc. | Oxidoreductase enzyme stabilized highly unsaturated fatty acids and derivatives of such acids |
GB2230442B (en) | 1989-02-16 | 1992-11-25 | Nat Res Dev | Controlled release device |
ATE131042T1 (de) * | 1990-04-25 | 1995-12-15 | Hoechst Ag | Pharmakologische zubereitung, enthaltend polyelektrolytkomplexe in mikropartikulärer form und mindestens einen wirkstoff. |
JPH0413724A (ja) | 1990-05-02 | 1992-01-17 | Chisso Corp | 可溶性ポリイミド、その製造法及び液晶配向膜用塗布液 |
JPH0413741A (ja) * | 1990-05-02 | 1992-01-17 | Chisso Corp | ペクチン・ポリリシン高分子電解質複合体 |
SE9002339L (sv) * | 1990-07-04 | 1992-01-05 | Kabi Pharmacia Ab | Terapeutisk komposition och foerfarande foer dess framstaellning |
KR930006431B1 (ko) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | 약물의 미세캡슐화 방법 |
ES2092808T3 (es) * | 1992-01-17 | 1996-12-01 | Alfatec Pharma Gmbh | Cuerpos solidos con contenido en principio activo con una estructura a base de macromoleculas hidrofilas y procedimiento para su produccion. |
FI920206A0 (fi) | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
US5718969A (en) * | 1993-08-25 | 1998-02-17 | Fmc Corporation | Nonaggregating hydrocolloid microparticulates, intermediates therefor, and processes for their preparation |
AU1751997A (en) * | 1996-01-30 | 1997-08-22 | Advanced Polymer Systems Inc. | Targeted delivery of drugs to the lower gastrointestinal tract |
CA2267116A1 (fr) * | 1996-10-09 | 1998-04-16 | Givaudan-Roure (International) S.A. | Procede de preparation de granules en tant qu'additif pour aliments |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
IL130303A0 (en) * | 1999-06-03 | 2000-06-01 | M G Novobiotech Ltd | A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
IL152127A0 (en) * | 2002-10-06 | 2003-05-29 | Bio Balance Corp | Probiotic compositions for the treatment of inflammatory bowel disease |
-
2002
- 2002-10-29 FR FR0213514A patent/FR2843302B1/fr not_active Expired - Lifetime
-
2003
- 2003-08-06 MX MXPA05001607A patent/MXPA05001607A/es active IP Right Grant
- 2003-08-06 JP JP2004528586A patent/JP2006500359A/ja active Pending
- 2003-08-06 AT AT03758212T patent/ATE432066T1/de not_active IP Right Cessation
- 2003-08-06 ES ES03758212T patent/ES2327630T3/es not_active Expired - Lifetime
- 2003-08-06 CA CA002495291A patent/CA2495291A1/fr not_active Abandoned
- 2003-08-06 WO PCT/FR2003/002474 patent/WO2004016248A2/fr active Application Filing
- 2003-08-06 US US10/524,318 patent/US7485294B2/en not_active Expired - Fee Related
- 2003-08-06 BR BR0313469-5A patent/BR0313469A/pt not_active Application Discontinuation
- 2003-08-06 CN CN038213656A patent/CN1681480B/zh not_active Expired - Fee Related
- 2003-08-06 AU AU2003274229A patent/AU2003274229B2/en not_active Ceased
- 2003-08-06 EP EP20080163660 patent/EP1992336A3/fr not_active Withdrawn
- 2003-08-06 DE DE60327772T patent/DE60327772D1/de not_active Expired - Lifetime
- 2003-08-06 EP EP03758212A patent/EP1526841B1/fr not_active Expired - Lifetime
- 2003-08-06 KR KR1020057002387A patent/KR101080577B1/ko active IP Right Grant
-
2008
- 2008-12-29 US US12/345,647 patent/US7833765B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN1681480A (zh) | 2005-10-12 |
EP1992336A2 (fr) | 2008-11-19 |
KR20050083628A (ko) | 2005-08-26 |
EP1526841A2 (fr) | 2005-05-04 |
WO2004016248A3 (fr) | 2004-04-08 |
AU2003274229B2 (en) | 2009-05-21 |
US7833765B2 (en) | 2010-11-16 |
EP1992336A3 (fr) | 2009-05-13 |
ES2327630T3 (es) | 2009-11-02 |
WO2004016248A2 (fr) | 2004-02-26 |
ATE432066T1 (de) | 2009-06-15 |
FR2843302B1 (fr) | 2004-10-22 |
US20090162339A1 (en) | 2009-06-25 |
CA2495291A1 (fr) | 2004-02-26 |
US20050249716A1 (en) | 2005-11-10 |
KR101080577B1 (ko) | 2011-11-04 |
US7485294B2 (en) | 2009-02-03 |
CN1681480B (zh) | 2010-04-14 |
FR2843302A1 (fr) | 2004-02-13 |
DE60327772D1 (de) | 2009-07-09 |
EP1526841B1 (fr) | 2009-05-27 |
AU2003274229A1 (en) | 2004-03-03 |
BR0313469A (pt) | 2005-07-12 |
JP2006500359A (ja) | 2006-01-05 |
MXPA05001607A (es) | 2005-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004016248A8 (fr) | Forme galenique pour la delivrance colique de principes actifs | |
AU2002357012A1 (en) | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof | |
WO2002070438A3 (fr) | Compositions permettant l'administration de biophosphonates | |
AU2001270300A1 (en) | Drug delivery formulations and targeting | |
HK1034183A1 (en) | Galenic formulations of meloxicam for oral administration. | |
AU2003229084A1 (en) | Methods and formulations for the delivery of pharmacologically active agents | |
WO2003082247A3 (fr) | Microparticules medicamenteuses | |
AU2003296897A1 (en) | Pharmaceutical formulations of camptothecine derivatives | |
WO2006060547A3 (fr) | Systemes et methodes d'administration intra-orale de medicaments | |
WO2001078680A3 (fr) | Compositions pharmaceutiques | |
WO2003026743A3 (fr) | Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives | |
IL161857A0 (en) | Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene | |
WO2005065660A3 (fr) | Formulations de ziprasidone | |
WO2003045306A3 (fr) | Composes phenoxy amine et compositions pour administrer des principes actifs | |
WO2004100926A3 (fr) | Materiaux pouvant etre traites a l'humidite pour la delivrance d'agents, procedes, et dispositifs medicaux | |
WO2002019969A3 (fr) | Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs | |
WO2003028696A8 (fr) | Compositions pour l'administration de combinaisons medicinales | |
EP2308479A3 (fr) | Composés et compositions pour la distribution d'agents actifs | |
WO2004032866A3 (fr) | Preparations therapeutiques | |
WO2005034999A3 (fr) | Composition pharmaceutique | |
AU2003246567A1 (en) | Administration form for the oral administration of active substances, vitamins, and/or nutrients | |
WO2004041158A3 (fr) | Compositions de rifalazil et regimes therapeutiques | |
WO2005039481A3 (fr) | Systeme d'administration de medicament par voie orale | |
WO2003041656A3 (fr) | Systeme de liberation prolongee de medicaments solubles | |
WO2002034240A3 (fr) | Formulations a liberation retardee et prolongee et procede d'utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 09/2004 UNDER (72, 75) THE NATIONALITY AND RESIDENCE OF "COUVREUR, PATRICK" SHOULD READ "¢FR/FR!" |
|
ENP | Entry into the national phase |
Ref document number: 2495291 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003274229 Country of ref document: AU Ref document number: 10524318 Country of ref document: US Ref document number: 2004528586 Country of ref document: JP Ref document number: PA/A/2005/001607 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002387 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003758212 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038213656 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003758212 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002387 Country of ref document: KR |